|
||
Bromhexine Uses |
||
Bromhexine SYRUP indicated for cough associated with wheeziness (bronchospasm) and tenacious phlegm (sputum).
Bromhexine is used to treat breathing difficulties caused by excessive mucus secretions in the air passages associated with respiratory tract infections.
Each tablet also contains lactose, maize or potato starch, gelatine and magnesium stearate as excipients.
The oral/inhalation solution also contains tartaric acid and methyl parahydroxybenzoate as excipients.
The syrup also contains tartaric acid, benzoic acid, sodium carboxymethylcellulose, glycerol, sorbitol solution, pharma flavor and ethanol as excipients.
Each capsule also contains lactose, cornstarch and magnesium stearate as excipients.
Bromhexine HCl is N-cyclohexyl-N-methyl-(2-amino-3,5-dibromobenzyl)amine hydrochloride.
Unless otherwise prescribed, the following doses are recommended:
Tablet: Adults and Children >12 years: 8 mg (1 tab) thrice daily; 6-12 years: 4 mg (½ tab) thrice daily; 2-6 years: 4 mg (½ tab) twice daily.
Inhalation Solution (with aerosol apparatus): It is generally recommended to warm inhalation solution to body temperature before inhalation. Patients with bronchial asthma may be advised to commencing inhalation after they have taken their regular bronchospasmolytic therapy.
Adults: 4 mL. Children >12 years: 2 mL; 6-12 years: 1 mL; 2-6 years: 10 drops; <2 years: 5 drops. All doses to be taken twice daily.
The solution may be diluted 1:1 in physiological saline solution. In order to avoid precipitation, the solution should be inhaled immediately after mixing. The combined administration of inhalation and oral application intensifies the effect, and is especially suited for the commencement of treatment in cases where the full effect is to be reached quickly.
Syrup: Adults and Children >12 years: 5 ml (1 tsp) thrice daily.
At commencement of treatment, it may be necessary to increase the total daily dose up to 48 mg in adults.
The syrup is sugar-free and therefore suitable for diabetics and small children.
Ampoule: Severe cases, before and after surgical intervention: 1 amp SC, IM or IV (duration of injection: 2-3 min) 2-3 times daily.
Capsule: Adults: 1 cap 3 times daily.
It is recommended for the initial phase of treatment usually lasting not more than a week.
Patients being treated with Bromhexine should be notified of an expected increase in the flow of secretions.
A reduction in dose of cardiac glycosides (e.g. digitalis) and quinidine might become necessary in patients suffering from congestive cardiac failure because of the positive inotropic effect of orciprenaline sulphate.
Bromhexine SYRUP should not be administered concomitantly with beta-blocking agents, due to orciprenaline’s reversal of anti-hypertensive action.
The concomitant use of other sympathomimetic agents should be carefully controlled to avoid potentiation of effects.
Bromhexine’s pharmacological action may lead to gastric irritation. A transient rise in serum aminotransferase values have been reported due to Bromhexine.
Orciprenaline sulphate, as a sympathomimetic agent, may precipitate a wide range of adverse effects. Side-effects include fear; anxiety, restlessness, tremor, insomnia, confusion, irritability, weakness and psychotic states. Appetite may be reduced and nausea and vomiting may occur. A rise in blood pressure which may produce cerebral haemorrhage and pulmonary oedema, tachycardia and cardiac arrhythmias, anginal pain, palpitations, and cardiac arrest. Hypotension with dizziness and fainting and flushing may occur. Other effects that may occur include difficulty in micturition and urinary retention; dyspnoea; weakness; headache; disturbances of glucose metabolism; sweating and hypersalivation. Muscle cramps or twitching or unpleasant taste may occur.
Bromhexine SYRUP is contra-indicated in patients with known hypersensitivity to sympathomimetic amines or any of the other ingredients; hypertrophic obstructive cardiomyopathy; and tachyarrhythmia.
Sympathomimetics, such as orciprenaline sulphate, may interact with monoamine oxidase inhibitors (MAOI), and therefore Bromhexine SYRUP should not be given to patients receiving such treatment or within 14 days of MAOI treatment termination.
Safety in pregnancy and lactation has not been established.
Bromhexine
Unit description / dosage (Manufacturer) | Price, USD |
Tablet; Oral; Bromhexine Hydrochloride 8 mg | |
Dragee; Oral; Bromhexine Hydrochloride 8 mg | |
Solution; Oral; Bromhexine Hydrochloride 4 mg / 5 ml | |
Syrup; Oral; Bromhexine Hydrochloride 4 mg / 5 ml | |
Tablet; Oral; Bromhexine Hydrochloride 4 mg | |
Tablet, Film-Coated; Oral; Bromhexine Hydrochloride 4 mg | |
Tablet, Film-Coated; Oral; Bromhexine Hydrochloride 8 mg | |
Drops; Oral; Bromhexine Hydrochloride 8 mg / ml | |
BROMHEXINE Liquid / 4mg per 5ml / 100ml units (IPCA Laboratories) | $ 0.54 |
BROMHEXINE Capsule/ Tablet / 8mg / 10 units (IPCA Laboratories) | $ 0.33 |
Bromhexine 8mg TAB / 10 | $ 0.33 |
Bromhexine / C.I. 8 mg x 1000's | |
Bromhexine / Winston 8 mg x 1000's | |
Bromhexine / Astar 8 mg x 1000's | |
Bromhexine / Prince 8 mg x 1000's | |
Bromhexine / S.Y. 2 mg/1 mL x 2 mL | |
8 mg x 10's | $ 0.33 |
Bromhexine / S.D. 8 mg x 1000's | |
Bromhexine / Y.C. 8 mg x 1000's | |
Bromhexine 110 ml Syrup | $ 0.01 |
Bromhexine 8 mg Tablet | $ 0.04 |
BROMHEXINE ELIXIR 1 bottle / 120 ML elixir each (Ipca Laboratories Ltd) | $ 0.98 |
BROMHEXINE TABLET 1 strip / 10 tablets each (Ipca Laboratories Ltd) | $ 0.50 |
BROMHEXINE tab 8 mg x 10's (IPCA (Intima)) | $ 0.42 |
Bromhexine 8mg Tablet (Ipca Laboratories Ltd) | $ 0.05 |
List of Bromhexine substitutes (brand and generic names): | |
Bromhexina Sintesina (Argentina) | |
Bromhexine 4 Berlin-Chemie (Georgia) | |
Bromhexine 8 Berlin-Chemie (Georgia) | |
Bromhexine Amriya (Egypt) | |
Bromhexine Berlin-Chemie (Georgia) | |
Bromhexine EG (Belgium) | |
Bromhexine EG-8 (Luxembourg) | |
Bromhexine Elixir Patar (Thailand) | |
Bromhexine Elixir Patar 4 mg/5 mL x 60 mL x 12's | |
Bromhexine Elixir Patar 4 mg/5 mL x 60 mL x 50's | |
Bromhexine Forte Jean-Marie (Hong Kong) | |
Bromhexine Forte Jean-Marie 8 mg x 100's | |
Bromhexine Forte Jean-Marie 8 mg x 1, 000's | |
Bromhexine Grindeks (Estonia, Latvia, Lithuania) | |
Bromhexine Hydrochloride | |
Bromhexine Hydrochloride 0.08% (Japan) | |
Bromhexine Hydrochloride 0.08% Isei (Japan) | |
Bromhexine Hydrochloride 0.2% (Japan) | |
Bromhexine Hydrochloride 0.2% Taiyo (Japan) | |
Bromhexine Hydrochloride Choseido (Japan) | |
Bromhexine Hydrochloride Isei (Japan) | |
Bromhexine Hydrochloride Kunihiro (Japan) | |
Bromhexine Hydrochloride Nichi-Iko (Japan) | |
Bromhexine Hydrochloride Taiyo (Japan) | |
Bromhexine Kanghe Pharm (China) | |
Bromhexine Nycomed (Georgia, Russian Federation) | |
Bromhexine Siphat (Tunisia) | |
Bromhexine Sopharma (Bulgaria) | |
Bromhexine Sopharma 2mg/ml (Bulgaria) | |
Bromhexine Sopharma 4mg/5ml (Bulgaria) | |
Bromhexine Sopharma 8mg (Bulgaria) | |
Bromhexine Sunward (Singapore) | |
Bromhexine Sunward 8 mg x 1's | |
Bromhexine Sunward 4 mg/5 mL x 1's | |
Bromhexine Tsiteli A (Georgia) | |
Bromhexine-Darnitsa (Georgia) | |
Bromhexine-Eurogenerics (Luxembourg) | |
Bromhexine-Grindeks (Estonia, Latvia, Lithuania) | |
Bromhexine-Kanghe Pharm (China) | |
Bromhexisal | |
Bromhexisal 1000 ml Syrup (Agrawal Pharmaceuticals) | $ 0.01 |
Bromhexyl (Vietnam) | |
Bromhexyl 8 mg x 1 Box | |
Bromicof (Mexico) | |
Bromifar (Indonesia) | |
Bromika (Indonesia) | |
Bromilar (Uruguay) | |
See 1860 substitutes for Bromhexine |
Users | % | ||
---|---|---|---|
> 60 | 2 | 33.3% | |
30-45 | 1 | 16.7% | |
1-5 | 1 | 16.7% | |
< 1 | 1 | 16.7% | |
16-29 | 1 | 16.7% |
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|